Cargando…

Radiomics for the Prediction of Response to Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study

Antifibrotic therapy has changed the treatment paradigm for idiopathic pulmonary fibrosis (IPF); however, a subset of patients still experienced rapid disease progression despite treatment. This study aimed to determine whether CT-based radiomic features can predict therapeutic response to antifibro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Cheng-Chun, Chen, Chin-Yu, Kuo, Yu-Ting, Ko, Ching-Chung, Wu, Wen-Jui, Liang, Chia-Hao, Yun, Chun-Ho, Huang, Wei-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028756/ https://www.ncbi.nlm.nih.gov/pubmed/35454050 http://dx.doi.org/10.3390/diagnostics12041002

Ejemplares similares

ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2021)

Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
por: Kang, Jieun, et al.
Publicado: (2021)

NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
por: Cheng, Shih-Lung, et al.
Publicado: (2022)

The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
por: Limper, Andrew H.
Publicado: (2019)

Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
por: Hadda, Vijay, et al.
Publicado: (2020)

Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
por: Kelly, Bryan T., et al.
Publicado: (2021)

Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics
por: Cottin, Vincent, et al.
Publicado: (2021)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study
por: Wu, Wen-Jui, et al.
Publicado: (2022)

Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
por: Iwanami, Yuji, et al.
Publicado: (2022)

Antifibrotic therapy in idiopathic pulmonary fibrosis candidates for lung transplantation undergoing pulmonary rehabilitation
por: Pereira, Monica Pruss, et al.
Publicado: (2023)

Effect of genotype on the disease course in idiopathic pulmonary fibrosis despite antifibrotic treatment
por: Sterclova, Martina, et al.
Publicado: (2021)

B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents
por: Roman, Jesse, et al.
Publicado: (2021)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
por: Li, Ji-Min, et al.
Publicado: (2023)

Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go
por: Assayag, Deborah
Publicado: (2021)

Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment
por: Kølner-Augustson, Line, et al.
Publicado: (2020)

A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia
por: Khan, Mohammed Ayaz, et al.
Publicado: (2023)

Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis
por: Mooney, Joshua, et al.
Publicado: (2021)

Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis
por: Skurikhin, Evgenii, et al.
Publicado: (2020)

Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives
por: Graney, Bridget A, et al.
Publicado: (2018)

Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
por: Casillo, Valeria, et al.
Publicado: (2019)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment
por: Balestro, Elisabetta, et al.
Publicado: (2019)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
por: Suzuki, Yuzo, et al.
Publicado: (2021)

National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
por: Salonen, Johanna, et al.
Publicado: (2022)

Functional xenon-129 magnetic resonance imaging response to antifibrotic treatment in idiopathic pulmonary fibrosis
por: Hahn, Andrew D., et al.
Publicado: (2023)

Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis
por: Murray, Lynne A., et al.
Publicado: (2017)

Antifibrotic Mechanism of Piceatannol in Bleomycin-Induced Pulmonary Fibrosis in Mice
por: Sheng, Hanjing, et al.
Publicado: (2022)

Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
por: Delanote, Isabelle, et al.
Publicado: (2016)

Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis
por: Aono, Yuya, et al.
Publicado: (2020)

Reduced Sialylation and Bioactivity of the Antifibrotic Protein Serum Amyloid P in the Sera of Patients with Idiopathic Pulmonary Fibrosis
por: Chen, Wensheng, et al.
Publicado: (2020)

HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis
por: Lyu, Xing, et al.
Publicado: (2019)

Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis
por: Kang, Jieun, et al.
Publicado: (2020)

Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis
por: Suzuki, Yuzo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r9fqfd42k04l1t7hqg52i4r4ss